Abstract 196P
Background
We sought to explore whether the circulating proliferative T lymphocyte subtypes in patients with advanced gastric cancer (AGC) can be used as an indicator of prognosis.
Methods
Blood samples were collected from patients with AGC before treatment and analyzed by fluorescence-activated cell sorting analysis. Patients were divided into two groups based on the ratio of CD8+ T cells to CD4+ T cells and the ratio of CD8+ T cells to CD4+ T cells within Ki-67+ T cells. Survival between the groups was compared using the Kaplan-Meier method and the log-rank test. Multivariate analyses were also performed.
Results
A total of 92 patients enrolled in the study. The median age was 64.2 years, and the male-to-female ratio was 2.3:1. The median survival duration was 12.5 months. No significant differences in progression-free survival (PFS) and overall survival (OS) were observed between the groups with high and low CD8/CD4 ratios. However, the group with a high ratio of CD8/CD4 within proliferating T cells (n = 46) had a significantly longer OS (16.8 months vs. 11.3 months; p = 0.011) compared to the group with a low ratio of CD8/CD4 within proliferating T cells (n = 46). PFS did not vary between these proliferating CD8/CD4 ratio groups. A multivariate analysis indicated that the ratio of proliferating CD8 to CD4 was an independent prognostic factor for OS.
Conclusions
A high CD8/CD4 ratio among proliferating T cells in circulation could be associated with a better prognosis in patients with AGC receiving first-line chemotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
592P - Treatment patterns and outcomes in patients with advanced non-small cell lung cancer with MET exon 14 skipping alterations in China
Presenter: Hanxiao Chen
Session: Poster Display
Resources:
Abstract
593P - MET TKIs in Asian patients (pts) with MET exon 14 skipping NSCLC: A matching-adjusted indirect comparison (MAIC)
Presenter: E-e Ke
Session: Poster Display
Resources:
Abstract
594P - The treatment pattern and clinical outcome in NSCLC patients with MET alteration: A retrospective real-world analysis in China
Presenter: Yongfeng Yu
Session: Poster Display
Resources:
Abstract
595P - Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)
Presenter: Koichi Goto
Session: Poster Display
Resources:
Abstract
596P - Repotrectinib in patients (pts) from Asia and China with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC): Results from the phase I/II TRIDENT-1 trial
Presenter: Ross Soo
Session: Poster Display
Resources:
Abstract
597TiP - A phase I/II study to evaluate the safety and anti-tumor activity of JIN-A02 in patients with EGFR TKI-refractory, EGFR-mutant advanced NSCLC
Presenter: Sun Min Lim
Session: Poster Display
Resources:
Abstract
598TiP - Exploration of aumolertinib in first-line treatment for advanced non-small cell lung cancer patients of performance status 3 with EGFR mutations (19del and L858R)
Presenter: Haiyi Deng
Session: Poster Display
Resources:
Abstract
599TiP - A prospective study of savolitinib plus docetaxel in pretreated EGFR/ALK/ROS1/METex14m-wildtype advanced NSCLC patients with MET overexpression (FirstMET)
Presenter: Shuting Zhan
Session: Poster Display
Resources:
Abstract
600TiP - Phase III study of telisotuzumab vedotin (Teliso-V) vs docetaxel in pretreated c-Met overexpressing EGFR wildtype (WT) non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC)
Presenter: Junko Tanizaki
Session: Poster Display
Resources:
Abstract
601P - Pembrolizumab in patients of Chinese descent with microsatellite instability-high/mismatch repair deficient advanced solid tumors: KEYNOTE-158
Presenter: Xiaohua Wu
Session: Poster Display
Resources:
Abstract